Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EMILIN2 regulates platelet activation, thrombus formation, and clot retraction.

PloS one·2015

Same author

Plasminogen regulates cardiac repair after myocardial infarction through its noncanonical function in stem cell homing to the infarcted heart.

Journal of the American College of Cardiology·2014

Same author

Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

The American journal of pathology·2014

Same author

Genetic dissection of quantitative trait Loci for hemostasis and thrombosis on mouse chromosomes 11 and 5 using congenic and subcongenic strains.

PloS one·2013

Same author

The plasminogen system in regulating stem cell mobilization.

Journal of biomedicine & biotechnology·2012

Same author

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Metabolism: clinical and experimental·2012

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Does plasmin have anticoagulant activity?

Jane Hoover-Plow¹

¹Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiovascular Medicine, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio 44195, USA. hooverj@ccf.org

Vascular Health and Risk Management

|April 22, 2010

Summary

Plasmin, the primary fibrinolytic enzyme, may also possess anticoagulant properties by inactivating key coagulation factors. While in vitro studies show strong evidence, in vivo data is limited, suggesting potential therapeutic applications.

Keywords:

anticoagulant blood cardiovascular disease plasminogen protease thrombosis

More Related Videos

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Area of Science:

Biochemistry
Hematology
Physiology

Background:

Hemostasis and thrombosis are regulated by coagulation and fibrinolytic pathways; imbalances lead to bleeding disorders or thrombosis.
The plasminogen system is central to fibrinolysis and also plays roles in extracellular matrix degradation and cell migration.
Emerging evidence suggests plasmin may cleave and inactivate coagulation factors, indicating potential anticoagulant functions beyond fibrinolysis.

Purpose of the Study:

To review in vitro and in vivo evidence for plasmin's inactivation of coagulation factors.
To evaluate the potential physiological role of plasmin as an anticoagulant.
To explore therapeutic applications of plasmin-mediated coagulation factor inactivation.

Main Methods:

Comprehensive literature review of in vitro studies on plasmin and coagulation factors.
Analysis of in vivo studies investigating plasmin's role in coagulation regulation.
Examination of experimental data on plasmin cleavage of coagulation factors FV, FVIII, FIX, and FX.

Main Results:

Multiple in vitro studies demonstrate plasmin's ability to cleave and inactivate coagulation factors FV, FVIII, FIX, and FX.
In vivo evidence supporting a physiological anticoagulant role for plasmin is currently lacking.
Plasmin's inactivation of coagulation factors shows potential for therapeutic use.

Conclusions:

Plasmin exhibits potent in vitro anticoagulant activity through the inactivation of critical coagulation factors.
A physiological role for plasmin as an anticoagulant in vivo requires further investigation.
Targeted plasmin activity could offer novel localized anticoagulant or combined thrombolytic/anticoagulant therapies.